Target intelligence / Profile preview

Ankyrin repeat and SOCS box protein 16 (ASB16)

Target
ASB16
Molecular classification
Substrate-recognition subunit of ECS-type E3 ubiquitin ligase complex, Adapter protein in Cullin-RING ligase complexes, Other (Ankyrin repeat family, SOCS box protein family)
01

Overview

Ankyrin repeat and SOCS box protein 16 (ASB16) is a member of the ASB protein family, which contains ankyrin repeat sequences for protein-protein interactions and a SOCS box domain known for coupling substrate proteins to the cellular degradation machinery via interaction with elongin B and C in ECS-type E3 ubiquitin ligase complexes. ASB16 may act as a substrate-recognition subunit for the recruitment and ubiquitination of specific cellular proteins, hence regulating their stability and turnover. It is implicated in pathways such as antigen processing and general protein metabolism and is thought to play roles in cancer, especially in the context of protein degradation. ASB16 itself is not currently targeted by any marketed drugs, and its direct role as a therapeutic target requires further exploration.

Other names
Ankyrin repeat and SOCS box containing 16ASB-16FLJ30165ankyrin repeat and SOCS box protein 16ankyrin repeat and SOCS box-containing protein 16
02

Mechanism of action

Alters substrate selection for ubiquitin-mediated proteasomal degradation when part of the ECS-type E3 ubiquitin ligase complex

03

Biological functions

Ubiquitination of substrate proteinsTargeting proteins for proteasomal degradationProtein-protein interactionRegulation of cellular protein levels
04

Disease associations

Cancer (functional variants have been associated with cancer risk; modulation suggested for cancer therapy)Other (likely linked to disorders mediated by altered protein degradation, though data are limited)
05

Safety considerations

None currently reported; safety, toxicity, or therapeutic challenges of direct modulation remain unexplored.
06

Interacting drugs

None currently described in the literature or protein/drug databases; no drugs are publically reported to selectively interact with ASB16.
07

Biomarkers

None established for patient selection or efficacy monitoring; however, ASB16-AS1 RNA levels have been studied as a prognostic marker in adrenocortical carcinoma.

Beyond the preview

Go deeper on Ankyrin repeat and SOCS box protein 16 (ASB16).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ankyrin repeat and SOCS box protein 16 (ASB16).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call